Alliancebernstein L.P. Decreases Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Alliancebernstein L.P. reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 29.2% in Q4, now holding 88,246 shares after selling 36,368 shares. Other investors, including Blue Trust Inc. and KBC Group NV, also adjusted their stakes. Insiders sold a total of 10,659 shares recently. Analysts have a "Moderate Buy" rating on the stock, with a target price averaging $56.36. Kymera's stock opened at $25.43, with a market cap of $1.65 billion, and reported a quarterly loss of $0.88 per share, missing estimates.
Alliancebernstein L.P. lowered its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 29.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 88,246 shares of the company's stock after selling 36,368 shares during the quarter. Alliancebernstein L.P. owned 0.14% of Kymera Therapeutics worth $3,550,000 as of its most recent filing with the SEC.
Get Kymera Therapeutics alerts:
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares during the last quarter. KBC Group NV boosted its position in Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after acquiring an additional 752 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Kymera Therapeutics during the 4th quarter valued at about $310,000. Arizona State Retirement System grew its stake in Kymera Therapeutics by 15.5% during the 4th quarter. Arizona State Retirement System now owns 11,221 shares of the company's stock valued at $451,000 after acquiring an additional 1,503 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Kymera Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 11,490 shares of the company's stock valued at $462,000 after acquiring an additional 3,026 shares during the last quarter.
Insiders Place Their Bets
In related news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock valued at $324,567 in the last ninety days. Insiders own 15.82% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on KYMR shares. HC Wainwright upped their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Citigroup started coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 target price for the company. Leerink Partners reiterated an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a report on Friday, December 27th. Finally, Stephens reissued an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $56.36.
View Our Latest Analysis on Kymera Therapeutics
Kymera Therapeutics Stock Up 5.4 %
Shares of KYMR opened at $25.43 on Tuesday. The company has a market cap of $1.65 billion, a P/E ratio of -10.87 and a beta of 2.22. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The firm's 50 day moving average price is $31.36 and its 200 day moving average price is $39.53.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.
Kymera Therapeutics Company Profile
(Free Report)Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Further Reading
- Five stocks we like better than Kymera Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- Growth Stocks: What They Are, What They Are Not
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- 3 Warren Buffett Stocks to Buy Now
- 3 Hot New IPOs Defying the 2025 Market Slump
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Kymera Therapeutics Right Now?
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
